IMV Inc. (IMV): Price and Financial Metrics

IMV Inc. (IMV): $0.82

0.02 (-2.55%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add IMV to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#269 of 381

in industry

IMV Price/Volume Stats

Current price $0.82 52-week high $12.70
Prev. close $0.84 52-week low $0.48
Day low $0.78 Volume 44,800
Day high $0.84 Avg. volume 233,607
50-day MA $0.64 Dividend yield N/A
200-day MA $3.23 Market Cap 9.63M

IMV Stock Price Chart Interactive Chart >


IMV Inc. (IMV) Company Bio


IMV Inc. operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma). DPX-Survivac is evaluated in multiple Phase 2 clinical trials across six cancer indications and also in combination with Merck's Keytruda in two clinical trials. The company is also advancing the development of a DPX-based vaccine candidate against COVID-19 in collaboration with infectious disease experts. In addition, it is developing DPX-RSV, a DPX-based vaccine candidate targeting the respiratory syncytial virus strain A. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.


IMV Latest News Stream


Event/Time News Detail
Loading, please wait...

IMV Latest Social Stream


Loading social stream, please wait...

View Full IMV Social Stream

IMV Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -94.97%
5-year -96.45%
YTD N/A
2023 0.00%
2022 -80.08%
2021 -60.39%
2020 6.21%
2019 -43.91%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!